Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
Riaz I, Siddiqi R, Islam M, He H, Riaz A, Asghar N, Naqvi S, Warner J, Murad M, Kohli M. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. JCO Clinical Cancer Informatics 2021, 5: 588-599. PMID: 34043431, DOI: 10.1200/cci.21.00035.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellClinical Trials, Phase II as TopicHumansKidney NeoplasmsNeoplasm Recurrence, LocalProgression-Free SurvivalProtein Kinase InhibitorsRandomized Controlled Trials as TopicConceptsAdjuvant tyrosine kinase inhibitorsTyrosine kinase inhibitorsRenal cell carcinomaTrial sequential analysisCell carcinomaTKI monotherapyClinical trialsHigh-risk renal cell carcinomaMultiple large clinical trialsKinase inhibitorsLiving Systematic ReviewRandomized phase 2High-risk patientsCertainty of evidenceLarge clinical trialsKey clinical outcomesAdverse event riskLack of benefitOS benefitPROTECT trialGRADE approachClinical outcomesRandomized trialsCancer recurrenceSTUDY SELECTION